Stephens Consulting, LLC Verve Therapeutics, Inc. Transaction History
Stephens Consulting, LLC
- $399 Billion
- Q1 2025
A detailed history of Stephens Consulting, LLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Stephens Consulting, LLC holds 70 shares of VERV stock, worth $401. This represents 0.0% of its overall portfolio holdings.
Number of Shares
70Holding current value
$401% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VERV
# of Institutions
203Shares Held
79.5MCall Options Held
204KPut Options Held
101K-
Alphabet Inc. Mountain View, CA12.3MShares$70.8 Million5.03% of portfolio
-
Bvf Inc San Francisco, CA6.9MShares$39.6 Million1.39% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$37.9 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY4MShares$22.9 Million2.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.96MShares$22.7 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $343M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...